Studies were carried out in humans and in rhesus monkeys to determine the role of the kidneys in the metabolism of circulating mevalonic acid (MVA). Following intravenous infusion of I'4CJMVA and 13Hlcholesterol, there was a rapid appearance of ['4Cjsqualene in the kidneys that exhibited a significantly longer half-life than plasma or hepatic squalene. In man and in rhesus monkeys there was a rapid equilibration between newly synthesized cholesterol from MVA and exogenously administered cholesterol in all tissues except the kidneys, where the specific activity ratio of newly synthesized to exogenous cholesterol was significantly higher. Estimates of the quantitative metabolism of intravenously infused radiolabeled MVA in the monkey demonstrated that 23% was excreted in the urine, 67% metabolized to cholesterol (58% in nonrenal tissues and 9% in the kidneys), and 10% catabolized to CO2 and nonsteroid products.
I'4CJMVA and 13Hlcholesterol, there was a rapid appearance of ['4Cjsqualene in the kidneys that exhibited a significantly longer half-life than plasma or hepatic squalene. In man and in rhesus monkeys there was a rapid equilibration between newly synthesized cholesterol from MVA and exogenously administered cholesterol in all tissues except the kidneys, where the specific activity ratio of newly synthesized to exogenous cholesterol was significantly higher. Estimates of the quantitative metabolism of intravenously infused radiolabeled MVA in the monkey demonstrated that 23% was excreted in the urine, 67% metabolized to cholesterol (58% in nonrenal tissues and 9% in the kidneys), and 10% catabolized to CO2 and nonsteroid products.
Measurements of MVA metabolism in anephric and uninephric patients demonstrate that, in the absence of renal uptake of MVA, exogenous and newly synthesized cholesterol achieve almost instantaneous equilibrium in the plasma; whereas in control subjects with normal renal function, this equilibration required at least 21 d for the two cholesterol decay curves to become parallel. These results suggest that the kidneys are solely responsible for the observed disequilibrium between newly synthesized and exogenous cholesterol; we suggest that this was due to the delayed release of newly synthesized cholesterol from the kidneys into the plasma compartment following intravenous infusion with radiolabeled MVA.
The data document the importance of the kidneys in the metabolism of circulating MVA. However, calculation of the quantative significance of this pathway in relation to whole body MVA metabolism indicates that renal metabolism of MVA accounts for -0.1% of daily MVA turnover, and that alterations in this pathway due to any form of renal pathology would not result in significant changes in hepatic or whole body sterol synthesis rates. We urge caution in the use of radiolabeled MVA in long-term kinetic studies of sterol metabolism because our data show that the plasma compartment Introduction Mevalonic acid (MVA)' is an obligate precursor in the biosynthetic pathway of all polyisoprenoid compounds, including cholesterol, and is the product of the key regulatory, ratelimiting enzyme in sterol biosynthesis, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (1) . Previous studies have demonstrated that MVA levels in plasma are regulated in vivo in animals (2) and in man (3) , and radiolabeled MVA has been used extensively in kinetic studies of squalene (4) , cholesterol (5) , and bile acid (6) synthesis in man under a variety of clinical situations.
The use of radiolabeled MVA as a precursor for in vivo kinetic studies of sterol metabolism is complicated by the fact that intravenously administered MVA is utilized by a number of metabolic pathways: catabolism to CO2 (7), cholesterol and bile acid synthesis (4, 6, 8) , and urinary excretion (9, 10) . In an attempt to correct for nonsteroid metabolism of intravenously administered [ '4C]MVA, and thereby calculate the actual dose of radiolabeled MVA converted to cholesterol in squalene kinetic measurements, we coadministered
[3H]cholesterol and determined the fractional conversion of MVA to cholesterol using the plasma cholesterol isotope ratio (4, 8) . Our studies indicated that the fractional conversion of MVA to cholesterol is variable but is directly related to the rate of whole body cholesterol synthesis in man (8) . Previously, we had demonstrated that the decay kinetics of newly synthesized and intravenously administered cholesterol were in disequilibrium for the initial 21 d following intravenous administration, after which time the decay curves were parallel for as long as 1 yr (Fig. 2, reference 4) . The forces contributing to this initial disequilibrium were not completely understood, but a number of animal studies suggested that renal metabolism of circulating MVA could be playing a role (11) (12) (13) (14) .
In the present study we have investigated 3H]Cholesterol was purified by thin-layer chromatography on silica gel G developed in benzene:ethyl acetate, 4:1 (vol:vol), and the purified cholesterol eluted with absolute ethanol. Radioisotopic materials were prepared and infused as previously described (4, 8) .
Patients (Table I) (4, 8) , the patient died from a myocardial infarction. At autopsy she was found to have atherosclerosis of the aorta and coronary arteries, aortic stenosis, bilateral arcus and xanthomata of the Achilles tendon and extensor tendons of the hands. Tissue samples were obtained at autopsy for determination of squalene and cholesterol masses and specific activities. All analytical procedures were carried out within 1 mo of obtaining the biopsy samples.
Patients V.F. and T.J. (Table I) were surgically anephric and were maintained on dialysis thrice weekly. Immediately following dialysis each patient was intravenously infused with R,S-[5-'4C]MVA (-5 uCi) and [1, , and blood samples were drawn over the subsequent 21 d for measurement of cholesterol specific activities to determine the fractional conversion of MVA to cholesterol (8) .
Other patients involved in this study (Table I ) and the individual study protocols are described in Results. For comparative purposes we have included data in this report from 15 control subjects (i.e., normal renal function and routine measurements of MVA fractional conversions) previously described (4, 8) . All 11 .3% of the total dose of the R-form of the radiolabeled MVA.
The plasma cholesterol specific activity and isotope ratio changed significantly over the 18-d study period (Table III) with the relative proportion of '4G-labeled cholesterol increasing steadily over the study period. Our The data presented in Table IV demonstrate the complete absence of plasma squalene radioactivity on day 2 and thereafter, which is consistent with its rapid turnover (4); however, significant amounts of radiolabeled squalene were found in the kidneys on day 2 and remain detectable up to day 15. These results are similar to those obtained from the autopsy of patient N.A. (Table II) and support the thesis that renal 1.8
As shown in Table X , analysis of the initial rate of equilibration of the isotope ratio of newly synthesized and exogenous cholesterol (see Fig. 1 Measurement of renal uptake ofplasma mevalonate. In an attempt to estimate the mass uptake of circulating MVA by the kidneys measurements of arterial-venous differences were carried out in patients undergoing surgery for carcinoma of the colon. While these data do not necessarily represent the normal in vivo situation (fasting, surgical trauma, unknown effects of anesthetics, etc.), they do provide some quantitative estimate of the ability of the kidneys to take up plasma MVA and, when combined with urinary output data, provide an estimate of MVA utilization via urinary excretion and catabolic processes. The arterial concentration of MVA in two such patients were 102 and 97 nM, and in renal vein plasmas were 48 and 71 nM, respectively. The renal uptake of MVA in these two subjects of 53 and 27% compare well with the data for arterial-venous differences found in the rat (2) and in the perfused rat kidney (16); these averaged -34%, which can be compared with the mean of 40% found in these two subjects. Analysis of the plasma MVA concentrations in the two anephric patients (T.J. and V.F.) demonstrated a significant 3 to 10-fold increase (468 and 141 nM, respectively) as compared with a mean value in control subjects of 45 nM (3, 10) ; thus, patients who lack the ability to clear circulating MVA via the renal pathway have significantly higher plasma MVA levels. Discussion MVA plays a central role in overall polyisoprenoid biosynthesis as the product of the rate-limiting enzyme HMG-CoA reductase t Control studies in patients with normal renal function previously reported (4, 8) .
are a major site of circulating MVA metabolism. One form of this metabolism involves renal uptake of MVA and its conversion to squalene in the tissue; this squalene is then slowly converted to cholesterol that equilibrates with the plasma cholesterol pool. In the single study carried out in an autopsied human subject, the renal squalene pool was found to be significantly radiolabeled; the cholesterol pool in the kidneys had a dose-normalized specific activity almost 30-fold greater than any other tissue 18 d after intravenous infusion with radiolabeled MVA. As determined by the ratio of the dosenormalized cholesterol specific activities of administered and newly synthesized cholesterol, only the kidneys showed a disproportionate enrichment with the sterol synthesized from radiolabeled MVA.
In the monkey studies, the time-course of this renal uptake (14) . In the human, urinary excretion of R-MVA and CO2 production account for a total of 39-46% of its catabolism. Thus, renal metabolism of circulating MVA in man appears to be the major site of MVA catabolism via three pathways: The apparent turnover of the labeled cholesterol from MVA would be expected to define kinetically the renal synthesis of cholesterol from the tracer; this process is significant in terms of radioactivity but not in terms of mass.
Quantitative significance of renal MVA metabolism. It has been hypothesized that impaired renal metabolism of MVA may play a significant role in the causation of the hypercholesterolemia prevalent in patients with renal diseases (27, 28) , diabetes (19) , thyroid dysfunction (20), and hypercholesterolemia (22) . The quantitative significance of the renal metabolism of MVA must be considered not by the analysis of intravenously infused radiolabeled MVA but rather by the actual flux of total MVA through the plasma compartment to the kidneys. The rate of flux of newly synthesized MVA from sites of synthesis in the tissues to the plasma compartment can be determined from three sorts of data: urinary MVA output and renal clearance; plasma MVA turnover data and plasma concentration measurements; and steady state MVA kinetic measurements of plasma MVA input rates (10) . Urinary output averages 2 gmol/d (9, 10) , accounting for 30% of the total renal flux of MVA (9); thus, the kidneys are exposed to -7 urmol MVA/d. Plasma MVA concentrations average -50 nM with a t112 of 40 min; this, in a 70-kg man, would represent a daily turnover of 3 ,umol/d (2, 10). Steady-state isotope infusion studies of plasma MVA kinetics provided data indicating that the plasma compartment constitutes a defined pool of MVA metabolism and that MVA flux through the plasma compartment equaled 6 Atmol/d (10) . The 
